Levofloxacin is a fluoroquinolone antimicrobial that exhibits antimicrobial activity by inhibiting bacterial topoisomerase II (DNA gyrase) and topoisomerase IV, enzymes required for DNA replication, transcription, repair, and recombination. Levofloxacin has a wide spectrum of activity against various Gram-positive bacteria, such as Corynebacterium species, Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae, Streptococci Group C/F, Streptococci Group G, and Viridans group streptococci. It is also effective against Gram-negative bacteria, including Pseudomonas aeruginosa, Acinetobacter lwoffii, Haemophilus influenzae, and Serratia marcescens.

Some studies have found that Levofloxacin is also indicated for post-operative ocular infections and endophthalmitis.

Resquin® Sterile Eye Drops is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms:

Aerobic Gram-positive bacteria: Corynebacterium species, Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae, Streptococcus (Group C/F), Streptococcus (Group G), Viridans group streptococci.Aerobic Gram-negative bacteria: Acinetobacter lwoffii, Haemophilus influenzae, Serratia marcescens.In some studies, Levofloxacin has also been found effective in post-operative ocular infections and endophthalmitis.

Days 1 & 2: Instill 1-2 drops in the affected eye(s) every 2 hours while awake, up to 8 times per day.
Days 3 to 7: Instill 1-2 drops in the affected eye(s) every 4 hours while awake, up to 4 times per day.

Resquin® is contraindicated in patients who are hypersensitive to Levofloxacin, other quinolones, or any of the components in this formulation.

The most frequently reported adverse reactions include transient decreased vision, fever, foreign body sensation, headache, ocular pain or discomfort, and photophobia. These events occurred in approximately 1-3% of patients. Other reported reactions, occurring in less than 1% of patients, include allergic reactions, lid edema, ocular dryness, and ocular itching.

Prolonged use may result in the overgrowth of non-susceptible organisms, including fungi. If superinfection occurs, discontinue use and initiate alternative therapy.

Patients wearing contact lenses should not use the drops while wearing the lenses.

This product should not be injected subconjunctivally, nor should it be introduced directly into the anterior chamber of the eye.

Specific drug interaction studies have not been conducted with topical Levofloxacin. However, systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline, interfere with caffeine metabolism, and transiently elevate serum creatinine levels in patients receiving systemic cyclosporine concomitantly.

There are no adequate and well-controlled studies in pregnant women. Levofloxacin should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Levofloxacin has not been measured in human milk. Based on data from Ofloxacin, it can be presumed that Levofloxacin is excreted in human milk. Caution should be exercised when administering Resquin® to a nursing mother.

Safety and efficacy in infants under the age of 1 year have not been established.

No overall differences in safety or efficacy have been observed between elderly patients and other adult patients.

Avoid contaminating the dropper tip with material from the eye, finger, or any other source.

The drug should be used within 30 days after first opening.
Store at 15-25°C.
Protect from light.
The bottle should be tightly closed immediately after use.